Survival analysis of 205 patients with glioblastoma multiforme: Clinical characteristics, treatment and prognosis in China

Glioblastoma multiforme outcomes of 107 patients treated in two Singapore institutions

“…Mexican (16) 1987-1994 16 20 Chinese (13) 1999- 2004 12 17 Korean (2) 1999- 2004 11 20 Italian (17) 2002- 2007 9 25 French (18) 2004- 2006 9 12 Scottish (19) 2004-2009 15 19 Singaporean (present study) 2002-2011 15 24 in local populations and environments mean that these models and calculators need to be validated locally before they can be employed. (19) The present study has shown that the prognostic factors in our local population are similar to those reported worldwide.…”

“…(7,(10)(11)(12) However, there has been no conclusive evidence that the clinical outcomes of GBM differ among ethnic groups. (13) Population-based studies conducted in Korea and China showed that the survival of Asian patients was similar to that of Western populations. (2,13) In one study that involved a racially diverse group of patients in America, there appeared to be improved survival among Asians as compared to other races.…”

“…(13) Population-based studies conducted in Korea and China showed that the survival of Asian patients was similar to that of Western populations. (2,13) In one study that involved a racially diverse group of patients in America, there appeared to be improved survival among Asians as compared to other races. (14) However, the authors hypothesised that the observed improved survival may be due to socioeconomic factors and access to care rather than intrinsic or genetic factors.…”

“…(2,13,(15)(16)(17)(18)(19) Earlier studies reporting outcomes during the pre-temozolomide era tend to show poorer survival outcomes when compared to recent studies that were conducted during the chemotherapy era. While our study includes the period before and after data from Stupp's seminal trial was published in 2005, most of our patients had received adjuvant concurrent temozolomide chemotherapy, which likely accounted for their better survival outcome.…”

Nuclear Factor Erythroid 2-Related Factor 2 and Heme Oxygenase-1 Protein Expression and Clinicopathological Features in Glioblastoma

“…However, local recurrence and distant metastasis are common posttreatment manifestations in patients. The overall five-year survival still remains poor with an average survival of 14 months after diagnosis [1] [2]. Moreover, various side effects are produced that can greatly influence a patient's quality of life.…”